Skip to main content

Table 1 all of the ncRNAs associated with chemotherapeutic resistance in BCa

From: Non coding RNAs as the critical factors in chemo resistance of bladder tumor cells

Study Year Gene Country Drug Results
Chen [17] 2020 MST1P2, miR-133b China Cisplatin MST1P2/miR-133b axis had an important role in cisplatin-resistance of bladder cancer through SIRT1/p53 pathway.
Chen [18] 2019 HIF1A-AS2 China Cisplatin HIF1A-AS2 enhances survival of tumor cells by upregulating HMGA1.
Wu [19] 2019 UCA1 China Rapamycin UCA1 acts as an endogenous sponge to down regulate the miR-582-5p which resulted in ATG7 over expression.
Zhang [20] 2017 GAS5 China Doxorubicin GAS5 increased doxorubicin-induced apoptosis through BCL-2 suppression.
Liu [21] 2019 MALAT1 China Cisplatin MALAT1 induced chemo resistance through regulating miR-101-3p/VEGFC axis.
Li [22] 2019 GHET1 China Gemcitabine GHET1 up regulated the MRP1.
An [23] 2018 FOXD2-AS1 China Gemcitabine FOXD2-AS1 indirectly targets the ABCC3 through miR-143 sponging.
Wang [24] 2017 MiR-143 China Gemcitabine The miR-143 attenuated gemcitabine resistance via IGF-1R suppression.
Fan [25] 2014 UCA1 China Cisplatin UCA1 overexpression was contributed to upregulation of WNT6.
Pan [26] 2016 UCA1 China Cisplatin, Gemcitabine UCA1 activates miR-196a-5p via CREB which results in gemcitabine/cisplatin resistance.
Xie [27] 2017 TUG1 China Doxorubicin TUG1 knockdown decreased Dox resistance through restraining the activity of Wnt/β-catenin pathway.
Xie [28] 2018 CDKN2B-AS China Gemcitabine CDKN2B-AS induced Gemcitabine-resistance via sponging Let-7.
Zhuang [29] 2017 LET China Gemcitabine TGFβ1 promotes gemcitabine resistance through LncRNA-LET/NF90/miR-145 axis.
Li [30] 2019 DLEU1 China Cisplatin DLEU1 up regulated the HS3ST3B1 via miR-99b suppression.
Zhao [31] 2019 NEAT1.1 China Cisplatin NEAT1.1 was down regulated following cisplatin treatment.
Xiao [32] 2018 MiR-22-3p China Paclitaxel, Adriamycin, Epirubicin, hydroxycamptothecin, Cisplatin, and Gemcitabine MiR-22-3p enhanced resistance to chemotherapy in bladder tumor cells through suppressing NET1.
Deng [33] 2015 MiR-27a China Paclitaxel, Adriamycin, Cisplatin MiR-27a/RUNX-1 pathway has a key function in chemo-resistance.
Drayton [34] 2014 MiR-27a UK Cisplatin MiR-27a deregulation induced cisplatin resistance in bladder cancer cells via up regulating SLC7A11.
Bu [35] 2014 MiR-101 China Cisplatin MiR-101 regulates cisplatin sensitivity in bladder tumor cell lines via targeting the COX-2.
Vinall [36] 2012 MiR-34a USA Cisplatin MiR-34a sensitized tumor cells to cisplatin by targeting SIRT-1 and CDK6.
Li [37] 2014 MiR-34a China Cisplatin MiR-34a targets CD44 after cisplatin therapy.
Liu [38] 2018 MiR-34a China Epirubicin MiR-34a significantly reduced Epirubicin chemo resistance in bladder tumor cells through targeting TCF1 and LEF1.
Zhang [39] 2017 MiR-34a China Cisplatin, Gemcitabine MiR34a regulation of GOLPH3 is active in bladder CSCs resistant to gemcitabine and cisplatin.
Tan [40] 2019 MiR-34b-3p China Paclitaxel, Adriamycin, Epirubicin, Cisplatin, Pirarubicin MiR-34b-3p attenuated chemo resistance in bladder cancer through suppressing CCND2 and P2RY1.
Luan [41] 2018 MiR-98 China Cisplatin, Doxorubicin MiR-98 promotes chemo-resistance through targeting LASS2.
Li [42] 2019 MiR-101-3p China Cisplatin MiR-101-3p decreased cisplatin-resistance in bladder urothelial carcinoma through repressing EZH2 and MRP1.
Cao [43] 2018 MiR-129-5p China Gemcitabine MiR-129-5p inhibits resistance to gemcitabine in bladder cancer cells and promotes their apoptosis via targeting WNT5a.
Lv [44] 2015 MiR-193a-3p China Pirarubicin, Paclitaxel,
Epirubicin Hydrochloride, and Cisplatin
MiR-193a-3p mediated HOXC9 down regulation which resulted in poorer sensitivity to chemotherapeutic drugs.
Deng [45] 2015 MiR-193a-3p China Pirarubicin, Paclitaxel, Adriamycin, Epirubicin hydrochloride, and Cisplatin PSEN1 was directly targeted by miR-193a-3p and executed its impact on the multi-chemo resistance.
Lin [46] 2017 MiR-193b-3p Taiwan Cisplatin CEBPD/miR-193b-3p axis had key roles in cisplatin response.
Deng [47] 2014 MiR-193a-3p China Paclitaxel, Adriamycin, Epirubicin Hydrochloride, and Cisplatin MiR-193a-3p induced multi-drug resistance in bladder cancer cells through down regulating LOXL4.
Lv [48] 2014 MiR-193a-3p China Pirarubicin hydrochloride, Paclitaxel, Adriamycin, and Epirubicin hydrochloride HIC2, SRSF2, and PLAU achieve their role in relaying miR-193a-3p’s effect on chemo resistance in bladder cancer through regulation of Myc/Max, NF-jB, DNA damage response, and NOTCH pathway.
Shindo [49] 2018 MiR-200b Japan Cisplatin TNFSF10, ICAM1, and IGFBP3 were induced in the resistant cells as a result of miR-200b + cisplatin treatment.
Zhang [50] 2015 MiR-203 China Cisplatin The miR-203 up regulation increased the cytotoxic effects of cisplatin and decreased tumor cell viability through suppressing Survivin and BCL-w.
Liu [51] 2018 MiR-214 China Cisplatin MiR-214 decreased chemo resistance in bladder cancer tissues and cell lines by suppressing NTN1.
Li [52] 2017 MiR-218 China Cisplatin MiR-218 up regulation reduced cisplatin resistance through GLUT1 targeting.
Zeng [53] 2016 MiR-222 China Cisplatin MiR-222 up regulation decreased cisplatin-induced apoptosis in bladder tumor cells through modulation of PPP2R2A/Akt/mTOR pathway.